DOSE ESCALATION OF NEXT GENERATION ANTI-CTLA-4 ANTIBODY ONC-392 IN COMBINATION WITH FIXED DOSE OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Hu-Lieskovan, Siwen [1 ]
He, Kai [2 ]
Tang, Mei [3 ]
Chen, Dan [4 ]
Liu, Yang [4 ]
Zheng, Pan [4 ]
Li, Tianhong [5 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Ohio State Univ, Canc Ctr, Columbus, OH 43210 USA
[3] Greater Baltimore Med Ctr, Baltimore, MD USA
[4] OncoC4 Inc, Rockville, MD USA
[5] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
594
引用
收藏
页码：A622 / A622
页数：1
相关论文
共 50 条
  • [31] Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
    Wilky, Breelyn A.
    Kumthekar, Priya
    Wesolowski, Robert
    Hwang, Jimmy J.
    Park, Steven I.
    Proscurshim, Igor
    Yuan, Guojun
    Dupont, Christopher D.
    Shebanova, Olga
    Cuillerot, Jean-Marie
    Dow, Edward
    Raizer, Jeffrey J.
    Gentry, Carleen
    Ross, Ainsley
    Drouin, Elise
    Wilson, Nicholas
    Goldberg, John M.
    Buell, Jennifer
    Stein, Robert Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients
    Colston, Elizabeth
    Grasela, Dennis
    Gardiner, David
    Bucy, R. Pat
    Vakkalagadda, Blisse
    Korman, Alan J.
    Lowy, Israel
    PLOS ONE, 2018, 13 (06):
  • [33] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Hollebecque, Antoine
    Gazzah, Anas
    Bahleda, Rastislav
    Menis, Jessica
    Champiat, Stephane
    El-Dakdouki, Yolla
    Paoletti, Xavier
    Ribrag, Vincent
    Michot, Jean-Marie
    Rafie, Saloomeh
    Planchard, David
    Besse, Benjamin
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    CANCER RESEARCH, 2018, 78 (13)
  • [34] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Besse, Benjamin
    Planchard, David
    Champiat, Stephane
    Angevin, Eroc
    Hollebecque, Antoine
    Bahleda, Rastislav
    Gazzah, Anas
    Armand, Jean-Pierre
    Paoletti, Xavier
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
    Taylor, Matthew H.
    Naing, Aung
    Powderly, John
    Woodard, Paul
    Chung, Luke
    Lin, Wen Hong
    Tian, Hongyu
    Siemers, Nathan
    Xiang, Hong
    Deng, Rong
    Hong, Kyu
    Valencia, Donna
    Huang, Tao
    Zhu, Ying
    Liao, X. Charlene
    Schebye, Xiao Min
    Patel, Manish R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (11)
  • [36] Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies
    Wilky, Breelyn A.
    Kumthekar, Priya
    Wesolowski, Robert
    Hwang, Jimmy J.
    Raizer, Jeffrey J.
    Gentry, Carleen
    Ross, Ainsley
    Drouin, Elise
    Wilson, Nicholas
    Shebanova, Olga
    Goldberg, John M.
    Buell, Jennifer
    Stein, Robert Benjamin
    Cuillerot, Jean-Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Angevin, Eric
    Tabernero, Josep
    Elez, Elena
    Cohen, Steven J.
    Bahleda, Rastilav
    van Laethem, Jean-Luc
    Ottensmeier, Christian
    Lopez-Martin, Jose A.
    Clive, Sally
    Joly, Florence
    Ray-Coquard, Isabelle
    Dirix, Luc
    Machiels, Jean-Pascal
    Steven, Neil
    Reddy, Manjula
    Hall, Brett
    Puchalski, Thomas A.
    Bandekar, Rajesh
    de Velde, Helgi van
    Tromp, Brenda
    Vermeulen, Jessica
    Kurzrock, Razelle
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2192 - 2204
  • [38] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [39] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [40] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
12345